Opportunity Information: Apply for PAR 16 058
Apply for PAR 16 058
- The HHS-NIH11 in the education, health sector is offering a public funding opportunity titled "Collaborative Research Projects to Enhance Applicability of Mammalian Models for Translational Research (Collaborative R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393, 93.394, 93.395, 93.396,.
- This funding opportunity was created on Dec 11, 2015 and posted on Dec 11, 2015.
- Applicants must submit their applications by May 07, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $450,000.00 in funding.
- Eligible applicants include: State governments, Public and State controlled institutions of higher education, Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
Collaborative Research Projects to Enhance Applicability of Mammalian Models for Translational Research (Collaborative R01) (PAR-16-058) is an NIH funding opportunity designed to support multi-site, team-based R01 research projects that make mammalian cancer and tumor models more useful for translational research. The central focus is on expanding, improving, or fundamentally transforming how mammalian models are built, characterized, and applied so they better reflect the biology of human cancers and can more reliably inform prevention, diagnosis, and treatment strategies. While the earlier version of this program (PAR-14-240) emphasized mouse models specifically, this FOA broadens the scope to include any mammalian cancer model, reflecting the need for a wider range of model systems that can capture different aspects of tumor biology and therapeutic response.
A defining feature of the program is its emphasis on true collaboration across multiple sites and disciplines. Applications are expected to come from teams that bring complementary expertise and resources that are difficult to assemble within a single lab or institution. The mechanism supports a linked set of collaborative R01s, meaning each participating site submits its own R01 with its own Program Director(s)/Principal Investigator(s), while the overall project is structured to operate as a coordinated effort. This setup is meant to encourage cross-site communication, shared planning, harmonized approaches, and integration of contributions, which is especially important for complex questions such as model development, comparative validation, standardized characterization, and multi-platform data generation.
The kinds of studies envisioned are those that go beyond what a single-site project can reasonably accomplish, such as coordinated development and testing of models across institutions, multi-lab validation of model fidelity and reproducibility, or integration of diverse technical approaches (for example, tumor biology, genomics, pathology, imaging, immunology, pharmacology, computational analysis, and clinical insight). The overarching goal is to produce mammalian cancer and tumor models that more accurately capture clinically relevant features of human disease, behave predictably under experimental and therapeutic conditions, and can be used with greater confidence to bridge the gap between basic research findings and clinical application.
Administratively, this is a discretionary grant opportunity from HHS/NIH (listed as HHS-NIH11) using the R01 grant funding instrument, aligned with health-related activity areas and associated with CFDA numbers 93.393, 93.394, 93.395, and 93.396. Eligibility is broad and includes state governments, public and private institutions of higher education, nonprofit organizations with or without 501(c)(3) status (with the noted exceptions), for-profit organizations other than small businesses, small businesses, and additional eligible applicants as described in the FOA’s eligibility clarification text. The posting and creation dates were December 11, 2015, and the closing date listed is May 7, 2017. The opportunity lists an award ceiling of $450,000, and the number of expected awards is not specified in the provided source information.
In practical terms, this FOA is aimed at accelerating the development and refinement of mammalian cancer models that are demonstrably better suited for translational research, while also pushing the field toward collaborative, multi-institutional strategies that improve rigor, comparability, and real-world applicability of model-based findings.
Frequently Asked Questions (FAQs)
What is the name of this NIH funding opportunity?
The opportunity is titled Collaborative Research Projects to Enhance Applicability of Mammalian Models for Translational Research (Collaborative R01) with FOA number PAR-16-058.
What is the main purpose of PAR-16-058?
Its purpose is to support multi-site, team-based R01 research projects that make mammalian cancer and tumor models more useful for translational research. The emphasis is on expanding, improving, or fundamentally transforming how these models are built, characterized, and applied so they better reflect human cancer biology and can more reliably inform prevention, diagnosis, and treatment strategies.
What types of models are in scope (mouse-only or broader)?
This FOA is broader than the earlier version of the program. While the prior program (PAR-14-240) emphasized mouse models, PAR-16-058 expands the scope to include any mammalian cancer model.
Why does this FOA emphasize mammalian models for translational research?
The FOA is focused on improving the ability of mammalian cancer and tumor models to reflect clinically relevant features of human disease, to behave more predictably under experimental and therapeutic conditions, and to be used with greater confidence to bridge basic research and clinical application.
What does NIH mean by “collaborative” in this FOA?
Collaboration is a defining feature. Projects are expected to involve multiple sites and disciplines, bringing together complementary expertise and resources that are difficult to assemble within a single lab or institution. The design is intended to support coordinated efforts with strong cross-site communication, shared planning, harmonized approaches, and integration of contributions.
Is this a single R01 application or multiple linked applications?
This mechanism supports a linked set of collaborative R01s. Each participating site submits its own R01 with its own Program Director(s)/Principal Investigator(s), while the overall project is structured to operate as a coordinated, multi-site effort.
What kinds of studies does the FOA encourage?
The FOA envisions studies that go beyond what a single-site project can reasonably accomplish, such as:
- Coordinated development and testing of mammalian cancer/tumor models across institutions
- Multi-lab validation of model fidelity and reproducibility
- Standardized characterization efforts
- Multi-platform data generation that benefits from coordinated, cross-site execution
What scientific approaches or disciplines might be involved in a competitive team?
The FOA describes collaboration across diverse technical approaches, which may include areas such as:
- Tumor biology
- Genomics
- Pathology
- Imaging
- Immunology
- Pharmacology
- Computational analysis
- Clinical insight
What is meant by improving how models are “built, characterized, and applied”?
Within the context provided, this means creating or refining mammalian cancer and tumor models and improving the ways they are evaluated and used so that they more accurately represent human cancers and generate results that are more reliable for translational decision-making.
What is the intended outcome or impact of funded projects?
The stated overarching goal is to produce mammalian cancer and tumor models that:
- More accurately capture clinically relevant features of human disease
- Behave predictably under experimental and therapeutic conditions
- Can be used with greater confidence to translate findings toward clinical application
- Promote rigor, comparability, and real-world applicability through multi-institutional strategies
Which agency and department sponsor this funding opportunity?
The sponsor is the National Institutes of Health (NIH) within HHS. The listing references HHS/NIH and includes the identifier HHS-NIH11.
What is the funding instrument/mechanism?
The funding mechanism is the R01 research project grant, specifically structured here as a collaborative, linked set of R01s across multiple sites.
Is this a discretionary grant opportunity?
Yes. The opportunity is described as a discretionary grant opportunity.
What are the activity areas associated with this FOA?
It is aligned with health-related activity areas, consistent with NIH’s mission and the FOA’s focus on cancer and tumor models for translational research.
What CFDA numbers are associated with this opportunity?
The opportunity is associated with CFDA numbers 93.393, 93.394, 93.395, and 93.396.
Who is eligible to apply (in general terms)?
Eligibility is broad and includes the following types of applicants (as stated in the provided information):
- State governments
- Public institutions of higher education
- Private institutions of higher education
- Nonprofit organizations with or without 501(c)(3) status (with noted exceptions)
- For-profit organizations other than small businesses
- Small businesses
- Additional eligible applicants as described in the FOA’s eligibility clarification text
Does the FOA require multiple institutions/sites?
The FOA is designed around true collaboration across multiple sites, with each site submitting a separate, linked R01 as part of a coordinated overall project.
What is the award ceiling for this opportunity?
The opportunity lists an award ceiling of $450,000.
How many awards will be made?
The number of expected awards is not specified in the provided information.
What are the posting and creation dates listed for this opportunity?
The posting and creation dates provided are December 11, 2015.
What is the closing date listed for this opportunity?
The closing date listed in the provided information is May 7, 2017.
How does this FOA differ from the earlier program PAR-14-240?
The earlier version (PAR-14-240) emphasized mouse models. PAR-16-058 broadens the scope to include any mammalian cancer model, reflecting the need for a wider range of model systems to capture different aspects of tumor biology and therapeutic response.
What is meant by “model fidelity” and “reproducibility” in the context of this FOA?
Based on the FOA description, “fidelity” refers to how well a model reflects key aspects of human cancer biology, and “reproducibility” refers to whether findings and model behavior can be validated consistently, including across multiple labs or institutions.
What kinds of collaborative benefits is NIH trying to promote through this program?
The FOA aims to promote cross-site coordination that improves:
- Rigor
- Comparability across labs and approaches
- Standardization of characterization
- Integration of multi-platform datasets
- Real-world applicability of model-based findings for translational research
Browse more opportunities from the same category: Education, Health
Next opportunity: USAID Child Blindness Program
Previous opportunity: 2016 National Geological and Geophysical Data Preservation Program
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 16 058
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 16 058) also looked into and applied for these:
| Funding Opportunity |
|---|
| Examination of Survivorship Care Planning Efficacy and Impact (R21) Apply for PA 16 011 Funding Number: PA 16 011 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Image-guided Drug Delivery (R01) Apply for PAR 16 044 Funding Number: PAR 16 044 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Promoting Caregiver Health Using Self-Management (R01) Apply for RFA NR 16 003 Funding Number: RFA NR 16 003 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $350,000 |
| Innovative Technologies for Cancer-Relevant Biospecimen Science (R21) Apply for RFA CA 16 003 Funding Number: RFA CA 16 003 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Mechanism for Time-Sensitive Drug Abuse Research (R21) Apply for PAR 16 055 Funding Number: PAR 16 055 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Small Cell Lung Cancer (SCLC) Consortium: Coordinating Center (U24 ) Apply for PAR 16 050 Funding Number: PAR 16 050 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $800,000 |
| Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33) Apply for RFA CA 16 002 Funding Number: RFA CA 16 002 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $300,000 |
| Advanced Development and Validation of Emerging Technologies for Cancer-Relevant Biospecimen Science (R33) Apply for RFA CA 16 004 Funding Number: RFA CA 16 004 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $300,000 |
| Small-Cell Lung Cancer (SCLC) Consortium: Therapeutic Development and Mechanisms of Resistance (U01) Apply for PAR 16 049 Funding Number: PAR 16 049 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $450,000 |
| Genomic Data Analysis Network: Processing Genomic Data Center (U24) Apply for RFA CA 15 018 Funding Number: RFA CA 15 018 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $660,000 |
| Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate the Discovery of Neurotherapeutics (R21/R33) Apply for RFA NS 16 013 Funding Number: RFA NS 16 013 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $250,000 |
| Small-Cell Lung Cancer (SCLC) Consortium: Innovative Approaches to the Prevention and Early Detection of Small Cell Lung Cancer (U01) Apply for PAR 16 051 Funding Number: PAR 16 051 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $450,000 |
| Examination of Survivorship Care Planning Efficacy and Impact (R01) Apply for PA 16 012 Funding Number: PA 16 012 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Proteome Characterization Centers for Clinical Proteomic Tumor Analysis Consortium (U24) Apply for RFA CA 15 021 Funding Number: RFA CA 15 021 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $800,000 |
| Innovative Questions in Symptom Science and Genomics (R15) Apply for PA 16 022 Funding Number: PA 16 022 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $300,000 |
| Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (R01) Apply for PA 16 035 Funding Number: PA 16 035 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Drug Discovery For Nervous System Disorders (R21) Apply for PAR 16 042 Funding Number: PAR 16 042 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $200,000 |
| Revision Applications for Assay Validation For High Quality Markers For NCI-Supported Clinical Trials (U10) Apply for PAR 16 056 Funding Number: PAR 16 056 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $150,000 |
| Innovative Questions in Symptom Science and Genomics (R01) Apply for PA 16 024 Funding Number: PA 16 024 Agency: HHS-NIH11 Category: Education, Health Funding Amount: Case Dependent |
| Global Noncommunicable Diseases and Injury Across the Lifespan: Exploratory Research (R21) Apply for PAR 16 052 Funding Number: PAR 16 052 Agency: HHS-NIH11 Category: Education, Health Funding Amount: $125,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 16 058", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.